Feedback Regulatory News (FDBK)

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Pilot Scheme with Sussex Integrated Care System to install Bleepa and CareLocker in Community Diagnostic Centres

· Pilot to be conducted with Queen Victoria Hospital NHS Foundation Trust (QVH) on behalf of Sussex Integrated Care System (Sussex ICS)

· Pilot to use Bleepa and CareLocker as a digital infrastructure to facilitate patient specific pathways through the Community Diagnostic Centres (CDC), linking both primary and secondary care settings

· £10bn CDC initiative announced by NHS England as a nationwide initiative and represents a significant commercial opportunity for Feedback

· CDC programme requires a secure, effective system of integrated clinical communication and secure individual patient records access to permit seamless data access across NHS constituents and CDCs: Feedback is well positioned to meet these needs through its recently launched clinical communication products and experience

London, 19 October 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it has entered into a memorandum of understanding (MOU) to embark on a pilot scheme to provide CDC services with Sussex ICS as one of the UK's CDC exemplar sites.

The CDC programme is a £10bn programme designed to help reduce the elective care backlog facing the NHS by bringing diagnostic investigations closer to patients in community settings. The programme is aimed at reducing the need for patients to attend hospital for diagnostic tests, enabling hospital facilities to be better utilised to manage inpatient and emergency services.[i] CDCs will provide a range of diagnostic investigations including medical imaging, blood tests, ECGs and eventually endoscopy services.

The pilot will use Feedback's digital infrastructure which includes Bleepa and CareLocker with the intention to identify the specification for bespoke development to meet the core CDC system needs of Sussex ICS. Feedback's primary product, Bleepa, provides a digital clinical communication platform to allow these investigations to be captured, associated with a specific patient journey and presented to clinicians in both primary and secondary care settings for review, discussion and planning onward management. The pathway record will then be stored centrally using Feedback's patient-specific CareLocker infrastructure to ensure its onward availability to all care settings.

The pilot is expected to run until March 2022 and will initially focus on delivering targeted CDC pathways in specific clinical areas such as respiratory and cardiology. It is anticipated that more pathways will be added as the pilot progresses with the ultimate aim of agreeing contractual terms for a commercial roll-out to CDCs. The terms of the MOU are non-binding.

As one of the first CDC sites to be launched in the UK, this pilot is expected to act as a blueprint model for how CDCs can be delivered. For CDCs to deliver their potential in streamlining patient journeys, accelerating investigation and decision making, it is essential that CDCs are connected to primary and secondary care settings and have the right digital infrastructure to present diagnostic information to these settings whilst facilitating cross-site communication. The Board believes that Feedback is uniquely placed to deliver this digital infrastructure through Bleepa and CareLocker combined given the products' abilities to share and store medical data and facilitate patient-specific case discussion across provider settings.

Dr Tom Oakley, CEO of Feedback, said: "The CDC programme sees the creation of an entirely new care setting and it needs the right digital infrastructure to ensure that it is fully integrated in order to deliver the intended system benefits and to drive down the elective care backlog. This is a once-in-a-generation opportunity to redesign care pathways and service delivery to our citizens. We are delighted to be working with such an innovative team across QVH and the wider Sussex ICS and are proud that Bleepa will feature in one of the showcases of the CDC programme. Connecting teams across care settings and presenting clinical data to drive faster decision making is precisely what Bleepa is designed to deliver. The CDC programme is an exciting opportunity for us to demonstrate our technology at a regional level and we believe that this will lead to a number of broader opportunities for Bleepa and our supporting technologies within the CDC programme and beyond."

Dr Ian Francis, Deputy Medical Director at QVH said: "We are very pleased to be working with Feedback and believe that the Bleepa platform will enable us to deliver cross-regional care aligned to designated clinical pathways. The patient-centric approach is core to our CDC proposal and the combination of Bleepa and CareLocker will allow us to deliver a connected CDC programme that maximises the impact for staff, patients and the wider system."

Further information on Bleepa can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

-Ends-

Enquiries:

Notes to Editors

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.